Sildenafil Citrate Therapy for Oligohydramnios
Pregnancy Complication
About this trial
This is an interventional treatment trial for Pregnancy Complication
Eligibility Criteria
Inclusion Criteria:
Pregnant women will be included if they are of:
- any age, any parity
- carrying a singleton pregnancy
- gestational age (GA) 30 weeks or more (based on the last menstrual period and confirmed by the results of ultrasound or determined through early pregnancy sonography)
- Amniotic fluid index ≤ 5
- no pregnancy complications such as preeclampsia, gestational hypertension, or diabetes
- no prior history of kidney, lung, and heart disease (the use of bolus-fluid therapy is contraindicated in these patients)
- intact fetal membranes.
Exclusion Criteria:
- Mothers treated with prostaglandin synthetase inhibitors
- well established labor
- evidence of fetal distress (non-reactive non stress test)
- fetal complications (intrauterine growth retardation or obvious fetal anomalies)
Sites / Locations
- Menoufia UniversityRecruiting
- Alhayah national hospitalRecruiting
- Alhayah national hospitalRecruiting
Arms of the Study
Arm 1
Arm 2
Active Comparator
Active Comparator
fluid therapy and sildenafil citrate
fluid therapy
Patients in first group will receive 2 liters of isotonic saline through intravenous infusion over a period of 4 hours using a rate of 250 ml per hour in addition to sildenafil citrate therapy (Viagra®) as 25 mg 3 times daily during hospitalization. After discharge patients in first group will be asked to continue sildenafil citrate therapy (Viagra®) as 25 mg 3 times daily plus a daily oral fluid intake of 2 liters
Patients in second group will receive 2 liters of isotonic saline through intravenous infusion over a period of 4 hours using a rate of 250 ml per hour. After discharge patients wil be asked to have 2 liters daily oral fluid